| dc.contributor.author | Roper, Jatin | |
| dc.contributor.author | Sinnamon, Mark J. | |
| dc.contributor.author | Coffee, Erin M. | |
| dc.contributor.author | Belmont, Peter | |
| dc.contributor.author | Keung, Lily | |
| dc.contributor.author | Georgeon-Richard, Larissa | |
| dc.contributor.author | Wang, Wei Vivian | |
| dc.contributor.author | Faber, Anthony C. | |
| dc.contributor.author | Yun, Jihye | |
| dc.contributor.author | Bronson, Roderick T. | |
| dc.contributor.author | Martin, Eric S. | |
| dc.contributor.author | Tsichlis, Philip N. | |
| dc.contributor.author | Hung, Kenneth E. | |
| dc.contributor.author | Yilmaz, Omer | |
| dc.date.accessioned | 2018-07-23T19:03:07Z | |
| dc.date.available | 2018-07-23T19:03:07Z | |
| dc.date.issued | 2014-02 | |
| dc.date.submitted | 2014-02 | |
| dc.identifier.issn | 0304-3835 | |
| dc.identifier.uri | http://hdl.handle.net/1721.1/117053 | |
| dc.description.abstract | PI3K inhibition in combination with other agents has not been studied in the context of PIK3CA wild-type, KRAS mutant cancer. In a screen of phospho-kinases, PI3K inhibition of KRAS mutant colorectal cancer cells activated the MAPK pathway. Combination PI3K/MEK inhibition with NVP-BKM120 and PD-0325901 induced tumor regression in a mouse model of PIK3CA wild-type, KRAS mutant colorectal cancer, which was mediated by inhibition of mTORC1, inhibition of MCL-1, and activation of BIM. These findings implicate mitochondrial-dependent apoptotic mechanisms as determinants for the efficacy of PI3K/MEK inhibition in the treatment of PIK3CA wild-type, KRAS mutant cancer. Keywords: PI3K; MEK; KRAS; Colorectal cancer; Mouse model of cancer | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.isversionof | http://dx.doi.org/10.1016/J.CANLET.2014.02.018 | en_US |
| dc.rights | Creative Commons Attribution-NonCommercial-NoDerivs License | en_US |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
| dc.source | PMC | en_US |
| dc.title | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer | en_US |
| dc.type | Article | en_US |
| dc.identifier.citation | Roper, Jatin et al. “Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer.” Cancer Letters 347, 2 (June 2014): 204–211 © 2014 Elsevier Ireland Ltd | en_US |
| dc.contributor.department | Koch Institute for Integrative Cancer Research at MIT | en_US |
| dc.contributor.mitauthor | Yilmaz, Omer | |
| dc.relation.journal | Cancer Letters | en_US |
| dc.eprint.version | Author's final manuscript | en_US |
| dc.type.uri | http://purl.org/eprint/type/JournalArticle | en_US |
| eprint.status | http://purl.org/eprint/status/PeerReviewed | en_US |
| dc.date.updated | 2018-07-13T16:24:20Z | |
| dspace.orderedauthors | Roper, Jatin; Sinnamon, Mark J.; Coffee, Erin M.; Belmont, Peter; Keung, Lily; Georgeon-Richard, Larissa; Wang, Wei Vivian; Faber, Anthony C.; Yun, Jihye; Yilmaz, Ömer H.; Bronson, Roderick T.; Martin, Eric S.; Tsichlis, Philip N.; Hung, Kenneth E. | en_US |
| dspace.embargo.terms | N | en_US |
| dc.identifier.orcid | https://orcid.org/0000-0002-7577-4612 | |
| mit.license | PUBLISHER_CC | en_US |